ClinicalTrials.gg
CompletedNCT00391274Updated Apr 12, 2011Results posted

Chemotherapy for Patients With Non-Small Cell Lung Cancer (NSCLC)

A Phase 3 interventional study of pemetrexed and docetaxel in Non-Small Cell Lung Cancer, sponsored by Eli Lilly and Company. Completed at 7 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-04-12.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
211
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung — 21 open to participants now, 32 under way, 11 of them phase 3. Pemetrexed · Carcinoma, Non-Small-Cell Lung.

Enrollment
51st of 223
211 · median 64
Started
2006
with 24 others
Phase 3
44 of 227
4 open now
Registered
45th of 227
by date
Lead sponsor
40 of 227
Eli Lilly and Company

Among the 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung, this one is the 51st largest by enrollment of the 223 interventional ones that give a count, is one of 25 that started in 2006, is one of 44 in phase 3, and was the 45th registered.

Carcinoma, Non-Small-Cell Lung

7,624 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

21 of the 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

16 more — sign in →

By country, each count listing its studies:

All 21 open studies →

About pemetrexed

Pemetrexed: first FDA approval 2004 (ALIMTA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The purpose of this study is to compare the efficacy and toxicity of pemetrexed and docetaxel administered on a 3-weekly schedule in the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have had prior chemotherapy.

03

Conditions studied

  • Non-Small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histologic or cytologic diagnosis NSCLC (Stage IIIA, IIIB, or IV), not amenable to curative surgery or radiotherapy
  • At least one prior chemotherapy for palliative therapy
  • (RECIST) criteria for disease status assessment
  • (ECOG) performance status 0 to 2

Exclusion criteria

Exclusion Criteria:

  • Concurrent administration of any other tumor therapy
  • Pregnant or breast feeding
  • Serious concomitant disorders
  • Inability or unwillingness to take folic acid or vitamin B12 supplementation
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
211 participants (actual)

Study arms

  • Experimental
    Pemetrexed

    Drug: pemetrexed

  • Active comparator
    Docetaxel

    Drug: docetaxel

Interventions

  • 500 mg/m2, intravenous (IV) every 21 days until disease progression, death or 12 months after enrollment

    Also known as: LY231514, Alimta

  • 75 mg/m2, intravenous (IV), every 21 days until disease progression, death or 12 months after enrollment

06

What researchers measure

Primary outcomes

  1. Overall Survival

    Overall survival was defined as the time from the date of study enrollment to the date of death due to any cause. Survival time was censored at the date of last contact for patients who were still alive or lost to follow-up. An amendment allowed for the collection of overall survival on an additional 43 survival events. At the time the original record was released, it was not possible to provide results with the 95% Confidence Interval (CI) since the upper limit was not calculable. The median and 95% CIs are now reported.

    Time frame: baseline to date of death from any cause (up to 24 months after study enrollment); amendment (up to 30 months after study enrollment)

Secondary outcomes

  1. Overall Tumor Response

    Response based on Response Evaluation Criteria In Solid Tumors (RECIST), which define when cancer patients improve ("respond"), stay the same ("stabilize"), or worsen ("progression") during treatments. CR (complete response) = disappearance of all target lesions; PR (partial response) = 30% decrease in the sum of the longest diameter of target lesions; PD (progressive disease) = 20% increase in the sum of the longest diameter of target lesions; SD (stable disease) = small changes that do not meet above criteria.

    Time frame: baseline to measured tumor response (up to 24 months after study enrollment)

  2. Progression-Free Survival (PFS)

    Progression-free survival (PFS) time was defined as the time from the date of study enrollment to the date of the first of the following events: objective disease progression or death due to any cause. For patients who were alive and had not progressed, PFS was censored at the last contact.

    Time frame: baseline to measured progressive disease (up to 24 months after study enrollment)

  3. Duration of Response

    Duration of tumor response is the duration from date of first objective status assessment of a complete or partial response to the first date of progression or death from any cause. For each patient who is not known to have died or to have had a progression of disease as of the data inclusion cut-off date, duration of tumor response was censored at the time of last prior contact. Due to the low number of patients in the analysis, the median duration of tumor response could not be calculated for the docetaxel arm. Available data are presented as "Number of Patients with Disease Progression".

    Time frame: time of response to progressive disease (up to 24 months)

  4. Pharmacology Toxicity

    Maximum common terminology criteria (CTC) Grade 3 or 4 toxicities possibly related to study drug are reported. The worst grade event per cycle is reported. Grades range from 0 (none) to 5 (death). Grade 3 events are severe and Grade 4 events are life-threatening.

    Time frame: first dose of study drug up to 24 months

07

Results

Posted Mar 30, 2010
Limitations and caveats
The primary outcome measure of this trial was designed to include pooled data. In addition, the results for the outcome on Duration of Response could not be presented due to the low number of patients being analyzed in the docetaxel group.

Participant flow

Participant flow — Overall Study
MilestonePemetrexedDocetaxel
Started107104
Received at least one dose of study drug106102
Completed4647
Not completed6157
Withdrew: Death due to study disease5545
Withdrew: Lost to follow-up03
Withdrew: Physician decision42
Withdrew: Withdrawal by subject03
Withdrew: Death due to adverse event13
Withdrew: Death due to indeterminate cause10
Withdrew: Death not study related01

Outcome measures

SecondaryOverall Tumor Response

Response based on Response Evaluation Criteria In Solid Tumors (RECIST), which define when cancer patients improve ("respond"), stay the same ("stabilize"), or worsen ("progression") during treatments. CR (complete response) = disappearance of all target lesions; PR (partial response) = 30% decrease in the sum of the longest diameter of target lesions; PD (progressive disease) = 20% increase in the sum of the longest diameter of target lesions; SD (stable disease) = small changes that do not meet above criteria.

Time frame:
baseline to measured tumor response (up to 24 months after study enrollment)
Reported as:
Number · participants
Overall Tumor Response
participantsPemetrexedDocetaxel
Complete Response00
Partial Response104
Stable Disease3346
Progressive Disease4936
Early Death from Malignant Disease76
Early Death from Other Causes11
Unknown45
Statistical analysis
  • Pemetrexed vs Docetaxel · Regression, Logistic · p = 0.1326 (Logistic regression of best overall tumor response (complete response + partial response).) · Odds ratio (or): 2.50 · 95% CI 0.76 to 8.25Treatment was the only covariate.
SecondaryProgression-Free Survival (PFS)

Progression-free survival (PFS) time was defined as the time from the date of study enrollment to the date of the first of the following events: objective disease progression or death due to any cause. For patients who were alive and had not progressed, PFS was censored at the last contact.

Time frame:
baseline to measured progressive disease (up to 24 months after study enrollment)
Reported as:
Median · months
Progression-Free Survival (PFS)
monthsPemetrexedDocetaxel
Progression-Free Survival (PFS)2.8 (1.8 to 3.1)3.1 (2.8 to 3.7)
Statistical analysis
  • Pemetrexed vs Docetaxel · Log Rank · p = 0.7704
  • Pemetrexed vs Docetaxel · Regression, Cox · p = 0.7784 · Hazard ratio (hr): 1.05 · 95% CI 0.75 to 1.46Treatment was the only covariate.
SecondaryDuration of Response

Duration of tumor response is the duration from date of first objective status assessment of a complete or partial response to the first date of progression or death from any cause. For each patient who is not known to have died or to have had a progression of disease as of the data inclusion cut-off date, duration of tumor response was censored at the time of last prior contact. Due to the low number of patients in the analysis, the median duration of tumor response could not be calculated for the docetaxel arm. Available data are presented as "Number of Patients with Disease Progression".

Time frame:
time of response to progressive disease (up to 24 months)
Reported as:
Median · months

No measurements were reported for this outcome.

SecondaryPharmacology Toxicity

Maximum common terminology criteria (CTC) Grade 3 or 4 toxicities possibly related to study drug are reported. The worst grade event per cycle is reported. Grades range from 0 (none) to 5 (death). Grade 3 events are severe and Grade 4 events are life-threatening.

Time frame:
first dose of study drug up to 24 months
Reported as:
Number · participants
Pharmacology Toxicity
participantsPemetrexedDocetaxel
Serum Glutamic Pyruvic Transaminase10
Hemoglobin73
Leukocytes421
Lymphopenia10
Neutrophils/Granulocytes529
Platelets70
Hypokalemia01
Anorexia10
Constipation01
Diarrhea05
Enteritis01
Fatigue (Asthenia, Lethargy, Malaise)35
Febrile Neutropenia24
Infection (Clinical/Microbiological: Neutrophils)01
Infection (Unknown: Pneumonia)01
Mucositis/Stomatitis10
Neuropathy: Motor01
Pain: Thorax Not Otherwise Specified (NOS)01
Pericardial Effusion (Non-Malignant)10
Pulmonary/Upper Respiratory - Other10
Rash/Desquamation10
PrimaryOverall Survival

Overall survival was defined as the time from the date of study enrollment to the date of death due to any cause. Survival time was censored at the date of last contact for patients who were still alive or lost to follow-up. An amendment allowed for the collection of overall survival on an additional 43 survival events. At the time the original record was released, it was not possible to provide results with the 95% Confidence Interval (CI) since the upper limit was not calculable. The median and 95% CIs are now reported.

Time frame:
baseline to date of death from any cause (up to 24 months after study enrollment); amendment (up to 30 months after study enrollment)
Reported as:
Median · months
Overall Survival
monthsPemetrexedDocetaxel
Overall Survival (up to 24 months)11.7 (8.7 to NA)12.2 (9.1 to NA)
Overall Survival (up to 30 months)11.4 (8.6 to 13.4)11.5 (8.9 to 15.2)
Statistical analysis
  • Pemetrexed vs Docetaxel · Regression, Cox · p = 0.4921 (P-value for Overall Survival (up to 24 months)) · Hazard ratio (hr): 1.14 · 95% CI 0.78 to 1.68Treatment was the only covariate.
  • Pemetrexed vs Docetaxel · Regression, Cox · p = 0.9256 (P-value for Overall Survival (up to 30 months)) · Hazard ratio (hr): 1.02 · 95% CI 0.74 to 1.40
Post-hocNumber of Patients With Disease Progression

Number of patients who have died or have had progression of disease. This outcome substitutes for the outcome on Duration of Response.

Time frame:
time of response to progressive disease (up to 12 months)
Reported as:
Number · participants
Number of Patients With Disease Progression
participantsPemetrexedDocetaxel
Number of Patients With Disease Progression41

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pemetrexed—10/106 (9.4%)99/106 (93.4%)
Docetaxel—12/102 (11.8%)95/102 (93.1%)
Most frequent serious events
Showing 10 of 20
Most frequent serious events
EventPemetrexedDocetaxel
Respiratory failureRespiratory, thoracic and mediastinal disorders3/1061/102
Febrile neutropeniaBlood and lymphatic system disorders2/1060/102
Pericardial effusionCardiac disorders2/1060/102
PyrexiaGeneral disorders2/1060/102
DyspnoeaRespiratory, thoracic and mediastinal disorders2/1061/102
AnaemiaBlood and lymphatic system disorders0/1061/102
NeutropeniaBlood and lymphatic system disorders0/1061/102
DiarrhoeaGastrointestinal disorders0/1061/102
Upper gastrointestinal haemorrhageGastrointestinal disorders0/1061/102
FatigueGeneral disorders1/1061/102
Most frequent other events
Showing 10 of 32
Most frequent other events
EventPemetrexedDocetaxel
FatigueGeneral disorders48/10642/102
AnorexiaMetabolism and nutrition disorders38/10630/102
Alanine aminotransferase increasedInvestigations33/10610/102
White blood cell count decreasedInvestigations15/10631/102
Neutrophil count decreasedInvestigations13/10630/102
DyspnoeaRespiratory, thoracic and mediastinal disorders31/10622/102
CoughRespiratory, thoracic and mediastinal disorders27/10624/102
Aspartate aminotransferase increasedInvestigations23/1066/102
NauseaGastrointestinal disorders21/10612/102
RashSkin and subcutaneous tissue disorders21/1064/102

Baseline characteristics

Age Continuous
Age Continuous(years)PemetrexedDocetaxelTotal
Mean56.4 ± 9.3355.9 ± 11.4156.1 ± 10.39
Sex: Female, Male
Sex: Female, Male(Participants)PemetrexedDocetaxelTotal
Female344377
Male7361134
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)PemetrexedDocetaxelTotal
East Asian107104211
Region of Enrollment
Region of Enrollment(participants)PemetrexedDocetaxelTotal
China107104211
Basis for Pathological Diagnosis
Basis for Pathological Diagnosis(participants)PemetrexedDocetaxelTotal
Cytological343569
Histopathological7369142
Disease Stage
Disease Stage(participants)PemetrexedDocetaxelTotal
Stage IIIA224
Stage IIIB241842
Stage IV8184165
Eastern Cooperative Oncology Group (ECOG) Performance Status
Eastern Cooperative Oncology Group (ECOG) Performance Status(participants)PemetrexedDocetaxelTotal
0 - Fully Active111627
1 - Ambulatory, Restricted Strenuous Activity8477161
2 - Ambulatory, No Work Activities121123
Number of Sites of Metastatic Disease
Number of Sites of Metastatic Disease(participants)PemetrexedDocetaxelTotal
1 Site101525
2 Sites323163
3 Sites343064
4 Sites111223
5 Sites11819
6 Sites4812
7 Sites303
8 Sites101
9 Sites000
10 Sites101

2 further baseline measures are reported on the registry.

08

Study locations

7 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Beijing, 101149, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Guang Zhou, 510080, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hang Zhou, 310022, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Nan Jing, 210002, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Shanghai, 200433, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tianjin, 300060, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Wu Han, 430030, China
09

References and documents

Publications

  • Wu YL, Sun Y, Zhou CC, Zhang L, Yu SY, Ma SL, Han LL, Zhang XQ, Orlando M. Survival without common toxicity criteria grade 3/4 toxicity following second-line treatment with pemetrexed for nonsquamous non-small cell lung cancer in Chinese patients. Chin Med J (Engl). 2013;126(24):4624-8. PubMed 24342300 ↗
  • Sun Y, Wu YL, Zhou CC, Zhang L, Zhang L, Liu XY, Yu SY, Jiang GL, Li K, Qin SK, Ma SL, Han L, Quinlivan M, Orlando M, Zhang XQ. Second-line pemetrexed versus docetaxel in Chinese patients with locally advanced or metastatic non-small cell lung cancer: a randomized, open-label study. Lung Cancer. 2013 Feb;79(2):143-50. doi: 10.1016/j.lungcan.2012.10.015. Epub 2012 Nov 20. PubMed 23182660 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2006, a primary completion of Dec 2008 and a completion of Jun 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2010, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 19, 2006
First posted
Oct 23, 2006
Start
Oct 2006
Primary completionActual
Dec 2008
CompletionActual
Jun 2010
Results first posted
Mar 30, 2010
Last update
Apr 12, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 12, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00391274
First posted
Oct 23, 2006
Start date
Oct 2006
Primary completion
Dec 2008
Completion
Jun 2010
Results posted
Mar 30, 2010
Last update
Apr 12, 2011

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pemetrexed

Start the discussion